Software aided approaches to structure-based metabolite identification in drug discovery and development

Drug Discovery Today: Technologies

Volumn 10, Issue 1, 2013, Pages

  Pähler, Axel ^a   Brink, Andreas ^a  

^a F Hoffmann La Roche   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE;

COMPUTER PREDICTION; COMPUTER PROGRAM; DATA ANALYSIS; DATA PROCESSING; DIGITAL FILTERING; DRUG IDENTIFICATION; DRUG METABOLISM; FOURIER TRANSFORM MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFORMATION PROCESSING; MASS SPECTROMETRY; MEDICAL DEVICE; MEDICAL INFORMATICS; METABOLITE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; WORKFLOW;

ANIMALS; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SOFTWARE;

EID: 84875729513     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.12.001     Document Type: Review

References (48)

1. A.C. Li Two-injection workflow for a liquid chromatography/LTQ-Orbitrap system to complete in vivo biotransformation characterization: demonstration with buspirone metabolite identification Rapid Commun. Mass Spectrom. 23 2009 3003 3012
2. Y. Liang Recent development in liquid chromatography/mass spectrometry and emerging technologies for metabolite identification Curr. Drug Metab. 12 2011 329 344
3. R.J. Mortishire-Smith Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis Rapid Commun. Mass Spectrom. 19 2005 2659 2670
4. E. Nagele, and A.S. Fandino Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast liquid chromatography time-of-flight mass spectrometry J. Chromatogr. A 1156 2007 196 200
5. A.E. Nassar, and P.E. Adams Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction Curr. Drug Metab. 4 2003 259 271
6. U.S. Department of Health and Human Services, Food and Drug Administration (CDER) Guidance for Industry Safety Testing of Drug Metabolites 2008 U.S. FDA Center for Drug Evaluation and Research http://www.fda.gov/cder/ guidance/index.htm
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. M3(R2) 2009 http://www.ich.org/products/guidelines/safety/ safety-single/article/guidance-on-nonclinical-safety-studies-for-the-conduct-of- human-clinical-trials-and-marketing-author.html
8. C.M. Dieckhaus Negative ion tandem mass spectrometry for the detection of glutathione conjugates Chem. Res. Toxicol. 18 2005 630 638
9. B.K. Park Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discov. 10 2011 292 306
10. N.J. Clarke Systematic LC/MS metabolite identification in drug discovery Anal. Chem. 73 2001 430A 439A
11. K.S. Hakala Feasibility of different mass spectrometric techniques and programs for automated metabolite profiling of tramadol in human urine Rapid Commun. Mass Spectrom. 20 2006 2081 2090
12. H.K. Lim Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap Rapid Commun. Mass Spectrom. 21 2007 1821 1832
13. C. Prakash Analytical strategies for identifying drug metabolites Mass Spectrom. Rev. 26 2007 340 369
14. T. Rousu Comparison of triple quadrupole, hybrid linear ion trap triple quadrupole, time-of-flight and LTQ-Orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro-amitriptyline and verapamil as model compounds Rapid Commun. Mass Spectrom. 24 2010 939 957
15. R.F. Staack, and G. Hopfgartner New analytical strategies in studying drug metabolism Anal. Bioanal. Chem. 388 2007 1365 1380
16. A. Tolonen Liquid chromatography-mass spectrometry in in vitro drug metabolite screening Drug Discov. Today 14 2009 120 133
17. M. Zhu Drug metabolite profiling and identification by high-resolution mass spectrometry J. Biol. Chem. 286 2011 25419 25425
18. S. Ma, and S.K. Chowdhury Analytical strategies for assessment of human metabolites in preclinical safety testing Anal. Chem. 83 2011 5028 5036
19. M. Trunzer Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation J. Med. Chem. 52 2009 329 335
20. Q. Ruan An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection J. Mass Spectrom. 43 2008 251 261
21. K.P. Bateman MSE with mass defect filtering for in vitro and in vivo metabolite identification Rapid Commun. Mass Spectrom. 21 2007 1485 1496
22. B. Bonn Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation Rapid Commun. Mass Spectrom. 24 2010 3127 3138
23. R. Alvarez-Sanchez Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry Chem. Res. Toxicol. 19 2006 1106 1116
24. K. Hobby A new approach to aid the characterisation and identification of metabolites of a model drug; partial isotope enrichment combined with novel formula elucidation software Rapid Commun. Mass Spectrom. 23 2009 219 227
25. I.D. Wilson High-performance liquid chromatography-mass spectrometry (HPLC-MS)-based drug metabolite profiling Methods Mol. Biol. 708 2011 173 190
26. K.O. Boernsen Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism Anal. Chem. 72 2000 3956 3959
27. G.J. Bruin A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: validation and applications J. Chromatogr. A 1133 2006 184 194
28. H. Zhang Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection Rapid Commun. Mass Spectrom. 22 2008 2082 2088
29. M.R. Anari, and T.A. Baillie Bridging cheminformatic metabolite prediction and tandem mass spectrometry Drug Discov. Today 10 2005 711 717
30. M.R. Anari Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir Anal. Chem. 76 2004 823 832
31. J.M. Castro-Perez Current and future trends in the application of HPLC-MS to metabolite-identification studies Drug Discov. Today 12 2007 249 256
32. A. Tarcsay, and G.M. Keseru In silico site of metabolism prediction of cytochrome P450-mediated biotransformations Expert Opin. Drug Metab. Toxicol. 7 2011 299 312
33. S. Ekins Computational prediction of human drug metabolism Expert Opin. Drug Metab. Toxicol. 1 2005 303 324
34. L.G. Valerio Jr., and A. Long The in silico prediction of human-specific metabolites from hepatotoxic drugs Curr. Drug Discov. Technol. 7 2010 170 187
35. B. Testa Predicting drug metabolism-an evaluation of the expert system METEOR Chem. Biodivers. 2 2005 872 885
36. H. T'Jollyn Evaluation of three state-of-the-art metabolite prediction software packages (Meteor, MetaSite, and StarDrop) through independent and synergistic use Drug Metab. Dispos. 39 2011 2066 2075
37. S. Boyer, and I. Zamora New methods in predictive metabolism Mol. Divers. 5 2002 277 287
38. G. Cruciani MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J. Med. Chem. 48 2005 6970 6979
39. I. Zamora Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9 J. Med. Chem. 46 2003 2313 2324
40. D. Zhou Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions Drug Metab. Dispos. 34 2006 976 983
41. G. Caron Predicting the oxidative metabolism of statins: an application of the MetaSite algorithm Pharm. Res. 24 2007 480 501
42. R.J. Vaz The challenges of in silico contributions to drug metabolism in lead optimization Expert Opin. Drug Metab. Toxicol. 6 2010 851 861
43. A. Pelander In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening Rapid Commun. Mass Spectrom. 23 2009 506 514
44. B. Prasad, and S. Singh Identification of rat urinary metabolites of rifabutin using LC-MSn and LC-HR-MS Eur. J. Pharm. Sci. 41 2010 173 188
45. D.D. Stranz Combined computational metabolite prediction and automated structure-based analysis of mass spectrometric data Toxicol. Mech. Methods 18 2008 243 250
46. L. Leclercq IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers Rapid Commun. Mass Spectrom. 23 2009 39 50
47. P.R. Tiller High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies Rapid Commun. Mass Spectrom. 22 2008 1053 1061
48. G. Schlotterbeck, and S.M. Ceccarelli LC-SPE-NMR-MS: a total analysis system for bioanalysis Bioanalysis 1 2009 549 559